MRNS Marinus Pharmaceuticals Inc.

1.4
+0.01  (+1%)
Previous Close 1.39
Open 1.38
Price To Book 1.57
Market Cap 73,610,366
Shares 52,578,833
Volume 598,401
Short Ratio
Av. Daily Volume 1,586,860
Stock charts supplied by TradingView

NewsSee all news

  1. Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RADNOR, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat

  2. Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial

    All patients achieved the primary endpoint Target Phase 3 dose identified Preparing for End-of-Phase 2 meeting with FDA Oral platform presentation at Neurocritical Care Society meeting in October Conference call and

  3. Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RADNOR, Pa, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data met primary endpoint - September 26, 2019. Data to be presented at Neurocritical Care Society Meeting on October 16, 2019 at 2:15 pm PDT.
Ganaxolone
Refractory status epilepticus (RSE)
Phase 2 negative data released July 23, 2019.
Ganaxolone - Magnolia
Postpartum depression
Phase 2 data released June 2016. Primary endpoint not met but intends to advance development
Ganaxolone
Fragile X Syndrome
Phase 3 data did not meet endpoints - June 2016
Ganaxolone
Focal onset seizures
Phase 3 top-line data due 3Q 2020.
Ganaxolone - Marigold
CDKL5 Deficiency Disorder (CDD)
Phase 3 top-line data due 2021.
Ganaxolone (Violet Study)
PCDH19-related epilepsy

Latest News

  1. Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RADNOR, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat

  2. Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial

    All patients achieved the primary endpoint Target Phase 3 dose identified Preparing for End-of-Phase 2 meeting with FDA Oral platform presentation at Neurocritical Care Society meeting in October Conference call and

  3. Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RADNOR, Pa, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat